- Home
- NEUP vs VYNE Comparison
NEUP vs VYNE Comparison
Compare NEUP & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- VYNE
- Stock Information
- Founded
- NEUP 1996
- VYNE 2003
- Country
- NEUP United States
- VYNE United States
- Employees
- NEUP N/A
- VYNE N/A
- Industry
- NEUP
- VYNE Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- VYNE Health Care
- Exchange
- NEUP Nasdaq
- VYNE Nasdaq
- Market Cap
- NEUP 10.3M
- VYNE 11.7M
- IPO Year
- NEUP N/A
- VYNE 2018
- Fundamental
- Price
- NEUP $4.36
- VYNE $0.39
- Analyst Decision
- NEUP Strong Buy
- VYNE Hold
- Analyst Count
- NEUP 2
- VYNE 1
- Target Price
- NEUP $28.00
- VYNE N/A
- AVG Volume (30 Days)
- NEUP 229.1K
- VYNE 1.5M
- Earning Date
- NEUP 11-14-2025
- VYNE 11-06-2025
- Dividend Yield
- NEUP N/A
- VYNE N/A
- EPS Growth
- NEUP N/A
- VYNE N/A
- EPS
- NEUP N/A
- VYNE N/A
- Revenue
- NEUP $15,649,448.00
- VYNE $524,000.00
- Revenue This Year
- NEUP N/A
- VYNE N/A
- Revenue Next Year
- NEUP N/A
- VYNE N/A
- P/E Ratio
- NEUP N/A
- VYNE N/A
- Revenue Growth
- NEUP N/A
- VYNE 6.29
- 52 Week Low
- NEUP $2.90
- VYNE $0.28
- 52 Week High
- NEUP $21.40
- VYNE $4.30
- Technical
- Relative Strength Index (RSI)
- NEUP 36.38
- VYNE 56.99
- Support Level
- NEUP $4.13
- VYNE $0.34
- Resistance Level
- NEUP $4.59
- VYNE $0.39
- Average True Range (ATR)
- NEUP 0.38
- VYNE 0.03
- MACD
- NEUP 0.30
- VYNE 0.00
- Stochastic Oscillator
- NEUP 22.94
- VYNE 77.76
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.